Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway

Targeting the tumor stroma is an important strategy in cancer treatment. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor-1 (PAI-1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI-1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells in vitro. It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL-6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI-1 expression was upregulated in TAMs after being stimulated with CAF-conditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelial-mesenchymal transition. CAFs were the main producer of C-X-C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI-1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI-1 secretion via CXCL12. Furthermore, it was found that PAI-1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs.

[1]  Z. Werb,et al.  Leveraging microenvironmental synthetic lethalities to treat cancer. , 2021, The Journal of clinical investigation.

[2]  Y. Kwon,et al.  p62-Induced Cancer-Associated Fibroblast Activation via the Nrf2-ATF6 Pathway Promotes Lung Tumorigenesis , 2021, Cancers.

[3]  S. Yuan,et al.  Adipocyte-Derived Leptin Promotes PAI-1-Mediated Breast Cancer Metastasis in a STAT3/miR-34a Dependent Manner , 2020, Cancers.

[4]  P. Dong,et al.  ERRα promotes pancreatic cancer progression by enhancing the transcription of PAI1 and activating the MEK/ERK pathway. , 2020, American journal of cancer research.

[5]  Yibin Kang,et al.  E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1. , 2020, Cancer letters.

[6]  C. Shyr,et al.  Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression , 2020, AntiCancer Research.

[7]  A. Vollmar,et al.  Thioholgamide A, a New Anti-Proliferative Anti-Tumor Agent, Modulates Macrophage Polarization and Metabolism , 2020, Cancers.

[8]  Mingdong Huang,et al.  Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. , 2020, Experimental cell research.

[9]  Lin Ma,et al.  SERPINE1 as a cancer-promoting gene in gastric adenocarcinoma: facilitates tumour cell proliferation, migration, and invasion by regulating EMT , 2019, Journal of chemotherapy.

[10]  Keqiu Jiang,et al.  Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma , 2019, Journal of Hematology & Oncology.

[11]  Y. DeClerck,et al.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding , 2019, Cancer and Metastasis Reviews.

[12]  Wei Yu,et al.  Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling , 2019, Cell Communication and Signaling.

[13]  Hong Tang,et al.  Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression , 2019, Journal of Hematology & Oncology.

[14]  Yu-jie Feng,et al.  α7-Nicotinic Acetylcholine Receptor Promotes Cholangiocarcinoma Progression and Epithelial–Mesenchymal Transition Process , 2019, Digestive Diseases and Sciences.

[15]  M. Okada,et al.  Inhibition of PAI‐1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer‐associated fibroblasts , 2019, Journal of cellular and molecular medicine.

[16]  Y. Kakeji,et al.  Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma , 2019, Laboratory Investigation.

[17]  G. E. Fernandez,et al.  Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. , 2018, Cell reports.

[18]  Yihai Cao,et al.  Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. , 2018, JCI insight.

[19]  Y. Morine,et al.  Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction , 2018, Cell Communication and Signaling.

[20]  Mintu Pal,et al.  Cadherin profiling for therapeutic interventions in Epithelial Mesenchymal Transition (EMT) and tumorigenesis , 2018, Experimental cell research.

[21]  N. Sun,et al.  Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance , 2018, Cell Death & Disease.

[22]  Darren R. Williams,et al.  Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion , 2018, Clinical Cancer Research.

[23]  Lin Zhang,et al.  Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α , 2018, Nature Communications.

[24]  Z. Werb,et al.  Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers , 2016, Nature Communications.

[25]  Noriyuki Nishimura,et al.  Collaboration of cancer‐associated fibroblasts and tumour‐associated macrophages for neuroblastoma development , 2016, The Journal of pathology.

[26]  Yuli Lin,et al.  FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. , 2016, Cancer research.

[27]  X. Wang,et al.  Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma , 2015, Hepatology.

[28]  Y. DeClerck,et al.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. , 2015, Cancer research.

[29]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[30]  Hongxin Ma,et al.  Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages , 2015, Gut.

[31]  S. Mashiko,et al.  Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer , 2015, Cancer biology & therapy.

[32]  Å. Borg,et al.  Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. , 2014, Cancer research.

[33]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[34]  E. Giannoni,et al.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression , 2014, Oncogene.

[35]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[36]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[37]  S. Goodison,et al.  Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model , 2013, Molecular Cancer Therapeutics.

[38]  N. Kohno,et al.  SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis , 2013, Molecular Cancer Therapeutics.

[39]  Y. DeClerck,et al.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. , 2012, Journal of the National Cancer Institute.

[40]  M. Olman,et al.  CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. , 2009, Biological & pharmaceutical bulletin.

[41]  G. Vlasuk,et al.  Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis , 2008, Journal of thrombosis and haemostasis : JTH.

[42]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[43]  B. Sobel,et al.  Inhibition of apoptosis and caspase‐3 in vascular smooth muscle cells by plasminogen activator inhibitor type‐1 , 2004, Journal of cellular biochemistry.

[44]  M. Burdick,et al.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  S. Goodison,et al.  Cell Cycle and Senescence PAI-1 Leads to G 1-Phase Cell-Cycle Progression through Cyclin D 3 / cdk 4 / 6 Upregulation , 2014 .

[47]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.